All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.
From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.
Here are five of the biggest stories to come out of ATTD 2022:
Dexcom’s G7 is accurate in pediatric T1D patients
Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.
The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.
Mean absolute relative difference (MARD), a measure of accuracy, came in at 8.1% for arm-placed sensors and registered at 9% for abdomen-placed sensors in the 7-17 years old group, while the 2-6 years old group provided an overall MARD of 9.3%.
Insulet’s Omnipod 5 improves HbA1c in T2D patients
Insulet (Nasdaq:PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system that back its use in both type 1 and type 2 diabetes patients.
The latest generation of the company’s wearable insulin pump already has an existing body of evidence for type 1, but showed promise for those with type 2.
Insulet said type 2 patients demonstrated significant HbA1c improvements (1.3%) and time in range improvements (4.6 hours per day) over the eight-week study. Hypoglycemia was also reduced by four minutes per day in the multiple daily injection group, while it did not change in the basal-only group, which had already shown very low rates of hypoglycemia.
Medtronic MiniMed 780G pump with next-gen Guardian 4 sensor offers improvements
The extended study phase of the Medtronic (NYSE:MDT) MiniMed 780G insulin pump system produced positive data demonstrating sustained improvements for users.
Data showed improvements in glycemic outcomes that met or exceeded consensus guideline recommendations of 70% time in range with less user interaction and fewer fingerstick calibrations.
In the study of the advanced hybrid closed loop (AHCL) system, time in range registered at 72.8%, with adults averaging 76.3% and children between seven and 17 years old averaging 70.7%. No episodes of diabetic ketoacidosis (DKA) or severe hypoglycemia occurred, while the average time spent in advanced hybrid closed loop mode came in at more than 90% across all age groups.
Abbott, CamDiab, Ypsomed partner on automated insulin delivery
Abbott (NYSE:ABT) partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system with an initial focus on European countries.
The partnership aims to design the integrated AID system to connect Abbott’s FreeStyle Libre 3 sensor — touted as the world’s smallest and most accurate continuous glucose monitoring sensor (CGM) with readings every minute — to CamDiab’s CamAPS FX mobile app, which connects with Ypsomed’s mylife YpsoPump.
By combining all devices and platforms in the partnership, the companies aim to create a smart, automated process for insulin delivery based on real-time glucose data. The wearable system will continuously monitor glucose levels and automatically adjust and deliver the proper amount of insulin at the right time.
Beta Bionics’ bionic pancreas delivers positive results
Beta Bionics designed its pocket-sized, wearable, investigational iLet device to autonomously dose insulin. Worn like an insulin pump, iLet users only enter bodyweight to initialize therapy without the need for insulin regimen parameters.
Primary analysis of an at-home study of 440 participants, which met all key endpoints, compared the iLet using Humalog or Novolog against the standard of care in 326 adults in children. The remaining 114 adult participants used iLet with Fiasp.
The iLet bionic pancreas produced a significant reduction in HbA1c — 0.5% — compared to those using the standard of care. There was no increased risk of hypoglycemia and time in range increased by an average of 2.6 hours more per day compared to the standard of care.
Even more news out of ATTD:
- Study results show improved time in range with Diabeloop automated insulin delivery system
- Analysis backs use of Abbott’s FreeStyle Libre CGM in type 1, type 2 diabetes
- One Drop touts study of digital diabetes management platform, plans to develop sensor
- Real-world evidence shows Tandem’s t:slim X2 insulin pump improves outcomes
- Welldoc says CGM, digital health platform combination provides better glycemic outcomes
- Study shows fewer out-of-target blood glucose levels using Ascensia’s monitoring system
- Data shows improved outcomes with DarioHealth’s chronic condition management platform
- Walmart unveils telehealth offering for managing diabetes
